MSMaryalice Stetler-Stevenson

Maryalice Stetler-Stevenson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryalice Stetler-Stevenson has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Constance M. Yuan

    G Laboratory of Pathology , CCR, NCI, NIH , Bethesda , MD , USA

    7 shared publications
  • Gregory A. Jasper

    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

    5 shared publications
  • Robert J. Kreitman

    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

    5 shared publications
  • David Venzon

    Biostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, MD, USA

    4 shared publications
  • Prashant R. Tembhare

    F Hematopathology Laboratory , Tata Memorial Hospital , Mumbai , India

    4 shared publications
  • Raul Braylan

    E Hematology Service, Department of Laboratory Medicine , CC, NIH , Bethesda , MD , USA

    4 shared publications

Latest Publications

  • Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma

    by Dalia Abdel-Raouf Salem, Neha Korde, David J. Venzon, David J. Liewehr, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant R. Tembhare, Constance M. Yuan, Carl Ola Landgren, et al.

    IL-6 activity in normal plasma cells (nPCs) and abnormal plasma cells (aPCs) is CD126 (subunit of IL-6 receptor) dependent. We quantified CD126 expression on nPCs and aPCs in monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and multiple myeloma (MM). CD126 was detected on all nPCs and aPCs indicating that CD126 does not have diagnostic utility. CD126 expression was higher in aPCs than in nPCs in 85% SMM but only 41% MGUS and there was evidence that CD126 was higher in aPCs than nPCs in the SMM (p = .048) but not MGUS (p = .96) patients. There is also a greater association between nPC and aPC CD126 expression in low risk MGUS than observed in high risk MGUS and SMM, suggesting normal regulation of CD126 decreases with disease progression. Future studies need to elucidate the role of bone marrow milieu versus escape from normal CD126 regulation in malignant transformation of clonal plasma cells.


  • Open Access

    Myeloma minimal residual disease testing in the United States: Evidence of improved standardization

    by Dalia Salem, Maryalice Stetler‐Stevenson, Constance Yuan, Ola Landgren


  • Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients.

    by Sham Mailankody, Neha Korde, Mark J. Roschewski, Austin Christofferson, Martin Boateng, Yong Zhang, Elisabet Esteve Manasanch, Dickran Gano Kazandjian, Mary Kwok, Manisha Bhutani, et al.

    8003 Background: Smoldering myeloma (SMM) is an ill-defined clinical myeloma precursor state. Recently, treatment studies targeting high-risk SMM patients have been conducted, showing promising clinical outcomes. Limited information is available on the biology of SMM. Using samples from a prospective clinical trial based on carfilzomib, lenalidomide and dexamethasone (CRd) (Korde et al. JAMA Oncology 2015), we showed near complete response (CR) or better in 28 of 45 (62%) patients with newly diagnosed multiple myeloma (NDMM); in high-risk SMM patients we reported stringent CR in 12 of 12 (100%) and 11 of 12 were MRD negative. Here, we sequenced the patients on our clinical trial and provide novel insights on tumor cell biology. Methods: We performed whole exome sequencing (median 125x, range 105-184x) and RNA sequencing of plasma cells obtained from baseline bone marrow samples in 39 patients with NDMM and 12 patients with high-risk SMM. Results: Whole exome sequencing on the 39 patients with NDMM identified a total of 2273 non-synonymous variants (median 53, range 26-139). Amongst the 12 SMM patients, 692 non-synonymous variants were identified (median 44, range 26-124). Previously reported recurrently mutated genes in multiple myeloma patients (BRAF, DIS3, FAM46C, IDH1, INTS12, IRF4, KRAS, NRAS, PRDM1, TP53, TRAF3, CYLD, RB1, ACTG1, LTB, HIST1H1E and MAX) were observed in 16 of 39 (41%) NDMM patients. In the high-risk SMM cohort, we did not detect any non-synonymous mutations amongst these genes. Conclusions: Amongst patients with NDMM and high-risk SMM enrolled in a prospective clinical trial of treatment with CRd, we confirmed previously reported recurrent mutations in NDMM. While the number of non-synonymous variants was similar in the two groups, none of the high-risk SMM patients had mutations in these genes. Our novel results suggest that at least a proportion of high-risk SMM patients have different molecular profiles compared to NDMM patients, which could have implications for risk determination and initiation of therapy. Additional analysis including clonal heterogeneity and subclonal architecture will be presented at the meeting. Clinical trial information: NCT01402284 and NCT01572480.


  • Open Access

    Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    by Maryalice Stetler‐Stevenson, Bruno Paiva, Lloyd Stoolman, Pei Lin, Jeffrey L. Jorgensen, Alberto Orfao, Jacques Van Dongen, Andy C. Rawstron

    Background: Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing.Methods: A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached.Results/Conclusion: The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society


  • Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method

    by Elisabet E. Manasanch, Dalia A. Salem, Constance M. Yuan, Nishant Tageja, Manisha Bhutani, Mary Kwok, Dickran Kazandjian, George Carter, Seth M. Steinberg, Diamond Zuchlinski, et al.

    Flow cytometry has increasing relevance for prognosis in myeloma and precursor disease (monoclonal gammopathy of unknown significance/smoldering myeloma), yet it has been reported that plasma cell enumeration by flow varies depending on the quality of marrow aspirate and field biopsied in patchy disease. We demonstrated increased sensitivity of flow over immunohistochemistry in abnormal-plasma cell detection in monoclonal gammopathy (n = 59)/smoldering myeloma (n = 87). We prospectively evaluated treatment-na ve smoldering myeloma (n = 9)/myeloma (n = 11) patients for the percentage of abnormal plasma cells/total plasma cell compartment, plasma cell viability/infiltration and flow immunophenotype depending on anticoagulant use, biopsy site and pull sequence in uni-and-bilateral bone marrow biopsies and aspirates. We found no statistical difference regarding the percentage of abnormal plasma cells, their immunophenotype or number/distribution in marrow samples even when obtained by different sequence in aspirates, or anticoagulants (p > 0.05). Our results show that plasma cell enumeration and immunophenotyping by flow cytometry is consistent under different conditions in these populations.


  • Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

    by Prashant R. Tembhare, Constance M. Yuan, David Venzon, Raul Braylan, Neha Korde, Elisabet Manasanch, Diamond Zuchlinsky, Katherine Calvo, Roger Kurlander, Manisha Bhutani, et al.


  • Open Access

    Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia

    by Prashant R. Tembhare, Gerald Marti, Adrian Wiestner, Heba Degheidy, Mohammed Farooqui, Robert J. Kreitman, Gregory A. Jasper, Constance M. Yuan, David Liewehr, David Venzon, et al.

    Objectives. Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainst


  • Diagnosis of hairy cell leukemia by flow cytometry

    by Maryalice Stetler-Stevenson, Prashant R. Tembhare

    Flow cytometric immunophenotpying (FCI) is a vital tool in the diagnosis of hairy cell leukemia (HCL). HCL has a distinctive immunophenotype based upon staining with antibodies to CD5 (negative), CD10 (negative), CD23 (negative), CD20 (abnormally bright), CD22 (abnormally bright), CD11c (abnormally bright), CD25 (abnormally bright), CD103 (positive), and CD123 (positive). Due to this unique immunophenotype, FCI can differentiate malignant hairy cells from normal B-cells and other lymphoproliferative disorders, especially the morphologically similar hairy cell leukemia variant and splenic lymphoma with villous lymphocytes. FCI is extremely sensitive in the detection of minimal disease and is useful in monitoring response to therapy.


  • Open Access

    Variables in the quantification of CD4 in normals and hairy cell leukemia patients

    by Lili Wang, Fatima Abbasi, Gregory A. Jasper, Robert J. Kreitman, David J. Liewehr, Gerald E. Marti, Maryalice Stetler-Stevenson

    Background: Quantitative flow cytometry (QFCM) is being applied in the clinical flow cytometry laboratory. Quantitative normal T‐cell CD4 expression represents a biologic standard and quality control agent. However, low levels of CD4 expression were detected in normal T‐cells in Hairy Cell Leukemia (HCL) samples. Methods: The QuantiBrite System® was used to determine the level of CD4 expression (mean antibody bound per cell, ABC) in fresh and shipped HCL blood and fresh normal donor blood (NDB). The effects of shipping, lysing reagent, cell preparation method, and antibody lot were evaluated. Results: Shipped HCL specimens (n = 69) had a significantly lower mean CD4 ABC of 38,788 (CV = 9.1%) compared to fresh specimens (n = 105) CD4 value of 40,330 (CV = 8.4%) (P < 0.05). In NDB, significant differences were seen for fresh versus shipped specimens using the stain/lyse method but not for lyse/stain method. Consistent differences in CD4 ABC based upon antibody lot were observed in fresh HCL and NDB samples. Stain/lyse and lyse/stain methods using NH4Cl lyse were compared in NDB using identical samples and antibodies. The NDB CD4 ABC values obtained with the lyse (NH4Cl)/stain method (45,562, 3.7% CV) were lower than those obtained with the stain/lyse (NH4Cl) method (49,955, 3.3% CV) with P < 0.001. Conclusions: CD4 expression in HCL patient samples is not inherently different from that observed in NDB and therefore may serve as a biological control in clinical QFCM. Technical variables impact significantly on QFCM of CD4. Published 2010 Wiley‐Liss, Inc.